Ramai Daryl, Shapiro Alexandra, Facciorusso Antonio, Bareggi Claudia, Gambini Donatella, Rijavec Erika, Tomasello Gianluca, Galassi Barbara, Ghidini Michele
Division of Gastroenterology and Hepatology, University of Utah School of Medicine, Salt Lake City, UT, USA (Daryl Ramai).
St George's University School of Medicine, True Blue, Grenada, West Indies (Alexandra Shapiro).
Ann Gastroenterol. 2022 Nov-Dec;35(6):568-576. doi: 10.20524/aog.2022.0746. Epub 2022 Oct 3.
Liver cancer is the third most common cause of cancer-associated death. Advances in the last decade have provided more options for treating hepatocellular carcinoma. The use of immune checkpoint inhibitors represents a leap forward and broadens the armamentarium for clinicians. In this article, we provide a state-of-the-art review of molecular therapy. We also detail the mechanisms of checkpoint inhibitor therapy, which blocks the interaction of programmed cell death receptor protein with programmed cell death ligand, reducing the immune checkpoint activity on regulatory T cells, thereby inhibiting tumor cell growth.
肝癌是癌症相关死亡的第三大常见原因。过去十年的进展为肝细胞癌的治疗提供了更多选择。免疫检查点抑制剂的应用代表了一个巨大进步，并拓宽了临床医生的治疗手段。在本文中，我们对分子疗法进行了最新综述。我们还详细阐述了检查点抑制剂疗法的机制，该疗法阻断程序性细胞死亡受体蛋白与程序性细胞死亡配体的相互作用，降低调节性T细胞上的免疫检查点活性，从而抑制肿瘤细胞生长。
